Eva Maria Ciruelos Gil

32PUBLICATIONS
259CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Dec 03, 2025
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa

|Dec 01, 2025
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.

Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Nov 03, 2025
Vacuum-assisted Biopsy and Surgical Correlation in HER2-positive and Triple-Negative Breast Cancer Subtypes in MRI Responders After Neoadjuvant Systemic Therapy. BISUCO TRIAL.

Sara Jimenez Arranz, Fernando Pizarro, Maria Angeles Fernandez Matamoros

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

Pageof 6

Frequent Collaborators

8 joint publications

Mafalda Oliveira

6 joint publications

Begoña Bermejo de Las Heras

5 joint publications

Aleix Prat

5 joint publications

Maria Vidal